What is Prealize?
Headquartered in Palo Alto, CA, Prealize operates at the intersection of artificial intelligence and healthcare. The company's core service revolves around proactive healthcare models designed to manage future health risks for its clients. By leveraging AI, Prealize aims to shift the paradigm from reactive treatment to predictive health management, offering a data-driven approach to improving patient outcomes and reducing healthcare costs. This strategic focus positions Prealize as a key player in the evolving health tech landscape.
How much funding has Prealize raised?
Prealize has raised a total of $30.9M across 3 funding rounds:
Private Equity
$2.8M
Series A
$6.1M
Series B
$22M
Private Equity (2017): $2.8M, investors not publicly disclosed
Series A (2017): $6.1M led by Stanford StartX, Premera Blue Cross, and Cardinal Partners
Series B (2019): $22M, investors not publicly disclosed
Key Investors in Prealize
Stanford StartX
Stanford StartX is an accelerator program that supports Stanford-affiliated entrepreneurs. Their involvement suggests a focus on early-stage, innovative technology ventures with strong academic roots.
Premera Blue Cross
Premera Blue Cross is a health insurance provider. Their investment indicates a strategic interest in companies that can improve healthcare delivery, reduce costs, or enhance member health outcomes.
Cardinal Partners
Cardinal Partners is a venture capital firm. While their specific focus isn't detailed here, their participation in this round suggests an interest in high-growth potential companies within the healthcare or technology sectors.
What's next for Prealize?
With substantial enterprise-level funding and a recent strategic investment, Prealize is poised for significant expansion. The company's focus on AI-driven proactive healthcare models suggests a trajectory towards further development and integration of its platform across various healthcare systems. Future initiatives are likely to involve enhancing its predictive analytics capabilities, forging new partnerships within the health sector, and potentially exploring new market segments. The sustained capital infusion indicates strong investor confidence in Prealize's mission to revolutionize health risk management through advanced technology.
See full Prealize company page
